As coro­n­avirus vari­ants trig­ger new alarms, the NIH is putting an un­der-the-radar ‘next-gen’ vac­cine in­to PhI

2 months ago
Discovery

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

2 months ago
Bioregnum

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it to the clin­ic

3 months ago
Financing

With a tor­rent of ven­ture cash gush­ing from a glob­al pack of uni­corn hunters, this biotech founder vows to stay hun­gry

3 months ago
Financing

A vet­er­an on­col­o­gy start­up crew is mak­ing a very se­ri­ous bet that they’ve found the key to un­lock­ing the promise of on­colyt­ic virus­es

3 months ago
Financing
Startups

It was the best of all pos­si­ble worlds in the worst of all times for biotech in 2020. What comes now?

3 months ago
Financing

John Con­nol­ly has a new mis­sion to tack on to his role at the Park­er In­sti­tute: in­ter­im chief of a buzzy biotech backed by a pair of bil­lion­aires

3 months ago
Bioregnum

Backed by a $200M in­vest­ment from a Ko­re­an con­glom­er­ate, Vivek Ra­maswamy has qui­et­ly built a ‘moth­er ship’ for vant cre­ation — with a whole new strat­e­gy in mind

4 months ago
Deals

The FDA spells out 4 rea­sons why it hates Min­er­va’s NDA ideas — but the biotech is go­ing for it any­way

4 months ago
FDA+

Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

4 months ago
Bioregnum
R&D

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

4 months ago
Bioregnum
FDA+

From a pair of Air Jor­dans to a $200M-plus IPO, Carl Hansen is craft­ing an overnight R&D for­tune fu­eled by Covid-19

4 months ago
Financing

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

4 months ago
R&D

Scoop: SR One crew com­pletes a com­pli­cat­ed spin­out from Glax­o­SmithK­line. And now they have a $500M fund to in­vest on their own

4 months ago
Financing

Rene­go­ti­ate the $6B CVR deal Bris­tol My­ers made for the Cel­gene buy­out? Caforio says that’s not hap­pen­ing

4 months ago
Deals

A phar­ma R&D chief jumps to a bud­ding new start­up fac­to­ry — and this time he’s found 'some­thing com­plete­ly dif­fer­ent’

5 months ago
People
Startups

What do the top 10 biotech M&A deals of 2020 tell us? Pre­mi­ums are in, bolt-ons rule and the ADC come­back is on

5 months ago
Startups
Deals

Sean Bo­hen just wrote the hand­book on how to make a quick for­tune in biotech

5 months ago
People
Financing

Lu­ca Santarel­li’s PhI­II is good to go, he has a new app to stop Covid-19 from in­fect­ing the da­ta and $110M to pave the way

6 months ago
Financing

A long-haul biotech with some im­pres­sive back­ers and big goals re­cruits a ma­jor league R&D ex­ec to the helm. What’s next?

6 months ago
People
Startups

Roche turns to a Har­vard up­start out of George Church’s lab to con­struct AAV 2.0 mod­el vec­tors — a key part of build­ing the gene ther­a­py pipeline

6 months ago
Deals
Cell/Gene Tx

What are the right in­gre­di­ents for a block­buster uni­corn IPO? Nor­bert Bischof­berg­er has some thoughts on that

6 months ago
Financing
Bioregnum

Af­ter re­cruit­ing an As­traZeneca vet as CEO to head a new team and rais­ing $139M cash, lit­tle Ole­ma ap­pears to be ready to launch … some­thing

6 months ago
Financing
R&D

Scoop: ARCH’s Bob Nelsen is back­ing an mR­NA up­start that promis­es to up­end the en­tire man­u­fac­tur­ing side of the glob­al busi­ness

6 months ago
Outsourcing
Cell/Gene Tx
First page Previous page 123456 Next page Last page